Esketamine as treatment for depression and PTSD
WorkSafeBC Evidence-Based Practice Group, Martin CW
Record ID 32018005169
English
Authors' objectives:
To explore results from systematic reviews/meta-analyses on the efficacy and
effectiveness of esketamine nasal spray as an adjunct treatment modality for depression
and post-traumatic stress disorder (PTSD).
Authors' results and conclusions:
Nine systematic reviews were included and were further appraised and are summarized in Table 1 (please refer to our paper). Esketamine for depression is generally studied as an adjunct treatment, generally together with a newly initiated antidepressant agent (SSRI or SNRI). Therefore, what is being studied is an additive benefit (or harm) from esketamine, rather than a direct effect in comparison with an antidepressant agent. At present, even if there seems to be a moderate level of evidence for the efficacy of intranasal esketamine in treating patients with depression for the short-term (less than four weeks, with best efficacy findings at 24 hours), there is not a sufficient number of studies on the long-term effects and safety related outcomes of esketamine.
Authors' methods:
A comprehensive and systematic literature search was conducted on commercial medical literature databases on August 8, 2022. We limited our search to publications in English and publications from 2015 onward. Manual searches were also conducted through the references of the articles that were retrieved in full text. For full inclusion and exclusion criteria, please refer to our paper.
Details
Project Status:
Completed
URL for project:
https://www.worksafebc.com/en/about-us/research-services/evidence-based-medicine-and-systematic-reviews
Year Published:
2023
English language abstract:
An English language summary is available
Publication Type:
Mini HTA
Country:
Canada
MeSH Terms
- Depression
- Depressive Disorder, Major
- Depressive Disorder, Treatment-Resistant
- Stress Disorders, Post-Traumatic
- Antidepressive Agents
- Ketamine
Keywords
- esketamine
- s-ketamine
- nasal ketamine
- spravato
- major depressive disorder
- mdd
- depression
- posttraumatic stress disorder
- ptsd
Contact
Organisation Name:
WorkSafeBC
Contact Address:
6591 Westminster Highway, Richmond, BC, V7C 1C6 Canada. Tel: 604-231-8417; Fax: 604-279-7698
Contact Name:
ebpg@worksafebc.com
Contact Email:
ebpg@worksafebc.com
Copyright:
WorkSafe BC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.